Browse the evidence

The mean weight loss in subjects who lost ≥5% of their initial body weight was 7.6±0.8 kg.

Practitioners can inform patients that achieving a 5% weight loss can result in an average loss of approximately 7.6 kg.

Teaching lifestyle modification and self-control plays a major role in reducing weight and BMI.

Practitioners should focus on teaching lifestyle changes and self-control strategies to enhance weight loss efforts.

Glucagon-like peptide-1 (GLP-1) agonists lead to greater weight loss in clinical trials and real-world settings than orlistat.

GLP-1 agonists may be a more effective pharmacological option for weight management in patients with obesity and inflammatory skin conditions.

GLP-1 receptor agonist patients experienced greater weight loss (7.8 kg) compared to controls (0.5 kg), with statistical significance (p<0.001).

Weight management strategies may be more effective in patients using GLP-1 receptor agonists.

Preoperative weight loss significantly improves long-term weight loss outcomes.

Encouraging preoperative weight loss may enhance surgical outcomes for patients.

AOM-naïve patients experienced superior weight loss outcomes with semaglutide compared to non-AOM-naïve patients at 3, 6, 9, and 12 months.

Practitioners should consider that patients who have not previously used anti-obesity medications may achieve better weight loss results with semaglutide.

Nutrition periodization is crucial for optimal performance and body composition in football players.

Coaches and nutritionists should tailor diets to training phases for better performance.

Increased protein and energy intake is recommended during the preparatory phase to support muscle mass development.

Increase protein and energy intake during the preparatory phase for muscle development.

Carbohydrates are emphasized for glycogen replenishment and recovery during the competitive period.

Focus on carbohydrate intake during competitive phases for optimal recovery.

Semaglutide treatment led to a weight decrease of 16 kg and a 36% reduction in insulin dose after 6 months in a patient with type 1 diabetes.

Semaglutide may be a beneficial treatment option for weight management in patients with type 1 diabetes.

Tirzepatide effectively reduces glucose levels and body weight in patients with type 2 diabetes and/or obesity.

Clinicians can consider tirzepatide as a treatment option for managing glucose levels and weight in these patients.

Weight control and an adequate diet are central strategies to prevent and treat T2DM.

Practitioners should focus on dietary interventions for T2DM prevention.

Weight loss by any means has been consistently shown to result in a rapid and marked improvement of metabolic disturbances.

Encouraging weight loss can lead to significant health improvements.

Tirzepatide (TZP) offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies.

Practitioners may consider TZP as a more effective treatment option for patients struggling to achieve glycemic control and weight loss.

Resistance training increased fat-free mass (FFM) and strength gains similarly in the three groups.

Resistance training is effective for increasing muscle mass and strength regardless of protein supplementation.

Fat-free mass (FFM) increased by 2.3% in the whey protein group, 3.6% in the chia flour group, and 3.0% in the placebo group.

The study provides specific data on how much FFM increased in each group, which can inform future research and practice.

UPFs increase the risk of chronic diseases and death.

Public health initiatives should address the risks associated with UPF consumption.

A 3-month regimen of nutrition counseling and high-intensity resistance training resulted in a 6.6% reduction in body fat and a 1.4% increase in muscle mass.

Practitioners can implement similar exercise and nutrition regimens to promote fat loss and muscle gain in breast cancer patients.

Participants demonstrated a 36.5% increase in composite load lifted across compound exercises.

Strength training protocols can effectively enhance lifting capacity in breast cancer survivors.

At 1-month follow-up, patients showed a 22.3 percent decrease in average fat tissue and a 21.5 percent increase in muscle mass.

The HIFEM+RF procedure can effectively reduce fat and increase muscle in the upper arms.

At 3-month follow-up, there was an average decrease in fat tissue by 25.5 percent and an average increase in muscle mass by 23.9 percent.

The HIFEM+RF procedure continues to show effectiveness in fat reduction and muscle gain over time.

The Innergy weight loss program achieved a mean weight loss of -6.8 lbs. among participants over 6 months (P<0.0001).

Practitioners can consider implementing the Innergy program for effective weight loss.

23% of participants lost 5.0% or more of their initial starting weight.

A significant portion of participants can achieve clinically meaningful weight loss.

Greater weight loss was associated with greater levels of participation in the program.

Encouraging higher participation may enhance weight loss results.